"Designing Growth Strategies is in our DNA"
Condyloma is a type of sexually transmitted disease resulting in wart-like growth in the area around the anus, glans penis, or vulva. Condyloma can be divided into three types, namely condyloma acuminatum (genital warts), condyloma latum and condyloma subcutaneum. Condyloma acuminatum or genital warts are most common among the three types and are caused by Human Papilloma Virus (HPV). The symptoms of Condyloma are increased vaginal discharge, grey spots in the genital area, Itching and discomfort in the genital area, grey or white lesions, and others.
Treatment for condyloma depends on the type of diseases. Medication for genital warts includes imiquimod, podophyllin, podofilox, trichloroacetic acid, sinecatechins, and others. Surgical methods for the treatment of genital warts are cryotherapy, surgical excision, electrocautery, and laser treatments.
Government initiatives for awareness regarding sexually transmitted diseases and preventive care have boosted the demand for condyloma drugs. Many clinical studies and research have been initiated for the development of new drugs for condyloma by pharmaceutical companies and research institutes. For instance; V501, which is being studied by Merck & Co., Inc., is currently in phase 3 clinical trials for the treatment of condyloma acuminata.
To know how our report can help streamline your business, Speak to Analyst
At present, around 42% of the pipeline candidates for Condyloma are in phase3 clinical stage. More than half of the studies are sponsored by industry.
The report on ‘Condyloma – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Condyloma. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Condyloma.
The report on ‘Condyloma – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.